Business Context and Reporting Period
This Form 6-K, dated January 24, 2003, incorporates Novartis AG's press release announcing full-year 2002 annual results. The reporting period covers the fiscal year ended December 31, 2002. Novartis reported record results for the sixth consecutive year, meeting its objective of double-digit sales growth in local currencies despite a strong Swiss franc.
Key Financial Metrics
| Metric | 2002 (CHF m) | 2002 (USD m) | 2001 (CHF m) | % Change (CHF) | % Change (Local Currencies) |
|---|---|---|---|---|---|
| Sales | 32,412 | 20,911 | 31,643 | 2% | 11% |
| Operating Income | 7,887 | 5,088 | 7,277 | 8% | 10% |
| Operating Margin | 24.3% | - | 23.0% | +1.3 pts | - |
| Net Income | 7,313 | 4,718 | 7,024 | 4% | - |
| Earnings Per Share (Basic) | CHF 2.91 | USD 1.88 | CHF 2.73 | 7% | - |
| Free Cash Flow (excl. acquisitions) | CHF 4,463 | - | CHF 4,073 | 10% | - |
| Net Liquidity | CHF 9,786 | - | CHF 13,475 | -27% | - |
| Debt/Equity Ratio | 0.20:1 | - | 0.21:1 | Improved | - |
Balance Sheet Highlights: Total equity decreased to CHF 39.7 billion due to share buybacks (CHF 4.8 billion) and translation losses, partially offset by net income. Total financial debts fell by CHF 0.9 billion. The company maintains a AAA credit rating.
Material Changes vs. Prior Period
- Currency Impact: A strong Swiss franc negatively impacted reported sales by 9 percentage points, compressing CHF growth to 2% despite an 11% increase in local currencies.
- Divisional Performance:
- Pharmaceuticals: Sales grew 13% in local currencies (4% in CHF), driven by cardiovascular (Diovan, Lotrel) and oncology (Gleevec, Zometa) franchises.
- Generics: Dynamic growth of 25% in local currencies (15% in CHF) due to geographic expansion and the acquisition of Lek (Slovenia).
- Consumer Health: Flat growth in CHF (0%) and local currencies (7% for ongoing businesses), with declines in OTC and Infant & Baby segments offset by CIBA Vision growth.
- Profitability: Operating income grew 8% in CHF, outpacing sales growth due to productivity gains and improved product mix. Operating margin expanded by 1.3 percentage points.
- Acquisitions & Divestitures: Acquired Lek (CHF 1.3 billion) and increased stake in Roche Holding AG (total 32.7% voting shares). Divested Food & Beverage business to Associated British Foods for CHF 402 million.
Guidance, Outlook, and Risks
- 2003 Outlook: Management expects dynamic sales growth to continue, driven by core Pharmaceuticals and key therapeutic areas. Pharmaceutical R&D investments are projected to increase by more than 20%, which is expected to decrease the Pharmaceuticals division's operating margin in 2003.
- Income Expectations: Despite higher R&D spend and lower anticipated financial income, both operating and net income are expected to exceed 2002 levels, barring unforeseen events.
- Reporting Currency: The Group will switch to reporting financial results in US dollars starting with the first quarter of 2003.
- Risks: Forward-looking statements are subject to risks including new clinical data, regulatory delays, patent challenges, and competition. Specific product risks include the safety profile of COX-2 inhibitors (Prexige) and the impact of generic competition on mature brands like Neoral.
Investor Verification Checklist
- Currency Translation: Verify the impact of the strong Swiss franc on reported CHF figures versus local currency growth, noting the planned switch to USD reporting in Q1 2003.
- R&D Investment Impact: Monitor Q1 2003 results to confirm the anticipated decrease in Pharmaceuticals operating margin due to the projected 20%+ increase in R&D spending.
- Product Pipeline: Track regulatory approvals for key pipeline products including Prexige (arthritis), Xolair (asthma), and Certican (transplantation).
- Share Repurchases: Confirm the cancellation of repurchased shares (approx. 24.6 million shares on the second trading line) at the upcoming Annual General Meeting to assess impact on EPS.
- Generics Integration: Review the integration progress and financial contribution of the newly acquired Lek business, which will be fully consolidated starting January 1, 2003.